A Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 14 Apr 2023
At a glance
- Drugs STI 6129 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Sorrento Therapeutics
Most Recent Events
- 10 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2022 Planned initiation date changed from 1 Oct 2022 to 1 Dec 2022.
- 16 Sep 2022 Planned End Date changed from 1 Dec 2025 to 1 Jul 2026.